Advantage Trust Co Makes New $60,000 Investment in Stryker Co. (NYSE:SYK)

Advantage Trust Co purchased a new stake in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, HoldingsChannel reports. The firm purchased 200 shares of the medical technology company’s stock, valued at approximately $60,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. US Asset Management LLC purchased a new stake in Stryker in the fourth quarter valued at $600,000. Wealthspire Advisors LLC boosted its stake in Stryker by 2.5% in the fourth quarter. Wealthspire Advisors LLC now owns 7,099 shares of the medical technology company’s stock valued at $2,126,000 after acquiring an additional 174 shares in the last quarter. Catalyst Financial Partners LLC increased its stake in Stryker by 3.0% in the fourth quarter. Catalyst Financial Partners LLC now owns 1,154 shares of the medical technology company’s stock valued at $346,000 after purchasing an additional 34 shares during the period. E Fund Management Co. Ltd. boosted its holdings in shares of Stryker by 14.9% in the fourth quarter. E Fund Management Co. Ltd. now owns 957 shares of the medical technology company’s stock valued at $287,000 after acquiring an additional 124 shares in the last quarter. Finally, Pinnacle Wealth Management Advisory Group LLC increased its holdings in Stryker by 19.3% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,334 shares of the medical technology company’s stock valued at $399,000 after buying an additional 216 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on SYK shares. TD Cowen lifted their price objective on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Truist Financial lifted their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Roth Mkm increased their price target on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Finally, Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a research note on Wednesday, January 31st. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $365.94.

Stryker Trading Up 0.5 %

NYSE SYK traded up $1.58 during mid-day trading on Thursday, hitting $330.86. The company’s stock had a trading volume of 980,396 shares, compared to its average volume of 1,327,501. The firm has a market capitalization of $126.04 billion, a P/E ratio of 37.77, a price-to-earnings-growth ratio of 2.54 and a beta of 0.91. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.71 and a quick ratio of 0.99. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The stock’s fifty day simple moving average is $345.60 and its two-hundred day simple moving average is $318.91.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The business had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.14 EPS. Research analysts expect that Stryker Co. will post 11.94 EPS for the current year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.